Answers are grounded in this paper and cite their sources.
Emerging evidence implicates α-synuclein oligomers as potential culprits in the pathogenesis of Lewy body disease (LBD). Soluble oligomeric α-synuclein accumulation in cytoplasm is believed to modify neuronal activities and intraneural Ca2+dynamics, which augment the metabolic burden in central neurons vulnerable to LBD, although this hypothesis remains to be fully tested. We evaluated how intracellular α-synuclein oligomers affect the neuronal excitabilities and Ca2+dynamics of pyramidal neurons in neocortical slices from mice. Intracellular application of α-synuclein containing stable higher-order oligomers (αSNo) significantly reduced spike frequency during current injection, elongated the duration of spike afterhyperpolarization (AHP), and enlarged AHP current charge in comparison with that of α-synuclein without higher-order oligomers. This αSNo-mediated alteration was triggered by spike-induced Ca2+release from inositol trisphosphate receptors (IP3R) functionally coupled with L-type Ca2+channels and SK-type K+channels. Further electrophysiological and immunochemical observations revealed that α-synuclein oligomers greater than 100 kDa were directly associated with calcium-binding protein 1, which is responsible for regulating IP3R gating. They also block Ca2+-dependent inactivation of IP3R, and trigger Ca2+-induced Ca2+release from IP3R during multiple spikes. This aberrant machinery may result in intraneural Ca2+dyshomeostasis and may be the molecular basis for the vulnerability of neurons in LBD brains.
No takes yet. Share an insight, caveat, or question.
Yamamoto et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: